AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15971073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy at 3.0 mg kg(‐1)
Number of subjects: 66
Study 15971073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy (both doses)
Number of subjects: 66
Study 12452021 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy combined with total body irradiation (TBI) or total lymph node irradiation (TLI)/subtotal lymph node irradiation (STLI)
Number of subjects: 11
Study 12452021 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy alone
Number of subjects: 11
Study 12452021 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary irradiation in the primary sites after transplantation
Number of subjects: 11
Study 12452021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (HDT combined with ASCT)
Number of subjects: 11
Study 12452021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related toxicity
Number of subjects: 11
Study 10609211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia
Number of subjects: 64
Study 10609211 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 64
Study 8461508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram/kg per min, low dose)
Number of subjects: 30
Study 8461508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (2 micrograms/kg per min, high dose)
Number of subjects: 30
Study 8461508 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 3954933 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of amoxycillin as a single i.v. infusion
Number of subjects: 24
Study 3954933 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ampicillin as a single i.v. infusion
Number of subjects: 24
Study 30328302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF)
Number of subjects: 80
Study 30328302 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser plus Sodium Fluoride (L+NaF)
Number of subjects: 80
Study 30328302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 30328302 — intervention group
Group type: EXPERIMENTAL
Intervention: Other treatments (CPP-ACPF, HA-NaF-X, L+CPP-ACPF, L+HA-NaF-X)
Number of subjects: 80
Study 25524404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU/week) for 6 months
Number of subjects: 25
Study 25524404 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 months of observation)
Number of subjects: 25
Study 25539330 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm
Number of subjects: 128
Study 25539330 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaMatrix
Number of subjects: 128
Study 23123549 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetic enucleation
Number of subjects: 80
Study 23123549 — intervention group
Group type: COMPARATOR
Intervention: bipolar transurethral resection
Number of subjects: 80
Study 21470370 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 24
Study 21470370 — intervention group
Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 24
Study 18049096 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐HYNIC‐rh‐annexin‐V scintigraphy (TAS)
Number of subjects: 38
Study 18049096 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analysis of ATU
Number of subjects: 38
Study 16616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-myocardial infarction angina pectoris (pre-MIAP)
Number of subjects: 110
Study 16616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior AMI
Number of subjects: 110
Study 14604742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg BID
Number of subjects: 1677
Study 14604742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg BID (adjusted for noncompliance)
Number of subjects: 1677
Study 14604742 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing fluvastatin without switching to another lipid‐lowering medication
Number of subjects: 1677
Study 14604742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1677
Study 10685657 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy (9 million IU/m2/d for 4 days, then 1.6 million IU/m2/d for 10 days)
Number of subjects: 79
Study 10685657 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 79
Study 9514403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine
Number of subjects: 316
Study 9514403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 9514403 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 316
Study 9514403 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 316
Study 9514403 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg folic acid
Number of subjects: 316
Study 9514403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation
Number of subjects: 316
Study 7825393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Sodium lauryl sulfate (SLS) dentifrice
Number of subjects: 10
Study 7825393 — intervention group
Group type: COMPARATOR
Intervention: SLS-free dentifrice
Number of subjects: 10
Study 3135934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Number of subjects: 0
Study 3135934 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Number of subjects: 0
Study 29603705 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine buccal infiltration
Number of subjects: 40
Study 29603705 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine inferior alveolar nerve block
Number of subjects: 40
Study 28185997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2mg daily) for 12 or 24 weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur.
Number of subjects: 0
Study 28185997 — intervention group
Group type: COMPARATOR
Intervention: Ulipristal acetate (5mg daily) for 12 weeks.
Number of subjects: 0
Study 28185997 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by active treatment for 12 weeks.
Number of subjects: 0
Study 28185997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2mg daily) in different regimens.
Number of subjects: 0
Study 26248820 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA only
Number of subjects: 1065
Study 26248820 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA+Clo
Number of subjects: 1065
Study 26248820 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet medication
Number of subjects: 1065
Study 26248820 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA or ASA+Clo
Number of subjects: 1065
Study 23431209 — intervention group
Group type: EXPERIMENTAL
Intervention: Region-specific spinal manipulation
Number of subjects: 148
Study 23431209 — intervention group
Group type: COMPARATOR
Intervention: Non-region-specific spinal manipulation
Number of subjects: 148
Study 20221953 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized aphasia treatment
Number of subjects: 0
Study 20221953 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 study of computerized aphasia treatment
Number of subjects: 0
Study 18171452 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label conditioned placebo dose reduction (CPDR) treatment
Number of subjects: 70
Study 18171452 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 70
Study 16996860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount-moderate intensity aerobic exercise (energy equivalent of approximately 19.3 km/wk at 40%-55% peak VO2)
Number of subjects: 193
Study 16996860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount-high intensity aerobic exercise (energy equivalent of approximately 19.3 km/wk at 65%-80% peak VO2)
Number of subjects: 193
Study 16996860 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount-high intensity aerobic exercise (energy equivalent of approximately 32.2 km/wk at 65%-80% peak VO2)
Number of subjects: 193
Study 16996860 — intervention group
Group type: COMPARATOR
Intervention: Inactivity (control group)
Number of subjects: 193
Study 14644721 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate (15 mg)
Number of subjects: 128
Study 14644721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11011475 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-based recruitment strategy
Number of subjects: 303
Study 11011475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 303
Study 8839380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiger Balm
Number of subjects: 0
Study 8839380 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 0
Study 8839380 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study 1363923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiazepam
Number of subjects: 0
Study 1363923 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam
Number of subjects: 0
Study 1363923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4005175 — intervention group
Group type: EXPERIMENTAL
Intervention: Young red cells (YRBC)
Number of subjects: 48
Study 4005175 — intervention group
Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 48
Study 4005175 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood
Number of subjects: 48
Study 31386583 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-muscle-training program (8 weeks)
Number of subjects: 17
Study 31386583 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily practice only)
Number of subjects: 17
Study 29395114 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 24
Study 29395114 — intervention group
Group type: COMPARATOR
Intervention: Cold Lateral Condensation (CLC)
Number of subjects: 24
Study 26335402 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg Q4W
Number of subjects: 1961
Study 26335402 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg Q4W
Number of subjects: 1961
Study 24057871 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-health intervention
Number of subjects: 215
Study 24057871 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated clinical and occupational care management
Number of subjects: 215
Study 22794222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cycling (MC) with apical pressure filling techniques (lateral compaction)
Number of subjects: 70
Study 22794222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cycling (MC) with apical pressure filling techniques (Tagger's hybrid)
Number of subjects: 70
Study 22794222 — intervention group
Group type: COMPARATOR
Intervention: Mechanical cycling (MC) alone
Number of subjects: 70
Study 22794222 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled groups (passive technique, lateral compaction, Tagger's hybrid)
Number of subjects: 70
Study 20554457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy combined with anterior corpus callosotomy (ATL + aCCT)
Number of subjects: 60
Study 20554457 — intervention group
Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 60
Study 20554457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior corpus callosotomy (aCCT)
Number of subjects: 60
Study 17140810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention study of back supports and education
Number of subjects: 454
Study 15608030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal contraceptive releasing 120 microg/day of etonogestrel and 15 microg/day of ethinylestradiol (EE) (group A)
Number of subjects: 51
Study 15608030 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 20 microg di EE and 150 microg of desogestrel (group B)
Number of subjects: 51
Study 15608030 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 51
Study 12200684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced courses of chemotherapy (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy)
Number of subjects: 159
Study 12200684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced courses of chemotherapy
Number of subjects: 159
Study 10429606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary bone-cement fixation with conventional plate and screw fixation
Number of subjects: 5
Study 7572320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dimethyl-APD (100-400 mg/day)
Number of subjects: 38
Study 7572320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dimethyl-APD (4 mg/day)
Number of subjects: 38
Study 7572320 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile response group
Number of subjects: 38
Study 2142705 — intervention group
Group type: EXPERIMENTAL
Intervention: Early thrombolytic therapy (administered at 7 hours)
Number of subjects: 1638
Study 2142705 — intervention group
Group type: EXPERIMENTAL
Intervention: Late thrombolytic therapy (administered at 11 hours)
Number of subjects: 1638
Study 2142705 — intervention group
Group type: EXPERIMENTAL
Intervention: Late thrombolytic therapy (administered at 17 hours)
Number of subjects: 1638
Study 2142705 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (timing not specified)
Number of subjects: 1638
Study 508503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 30
Study 508503 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 30
Study 508503 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg (Scherer formulation)
Number of subjects: 30
Study 508503 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone 100 mg
Number of subjects: 30
Study 508503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30247159 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 40
Study 30247159 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 40
Study 28928176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CONUT scores
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Higher body mass index (24.25±3.05)
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Higher haemoglobin (123.78±17.05)
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Higher albumin levels
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Lower fasting blood glucose (6.90±2.48)
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Higher GNRI score (99.42±6.55)
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: Lower CONUT (3.13±1.98)
Number of subjects: 336
Study 28928176 — intervention group
Group type: COMPARATOR
Intervention: High-CONUT group
Number of subjects: 336
Study 28928176 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CONUT risk
Number of subjects: 336
Study 28928176 — intervention group
Group type: EXPERIMENTAL
Intervention: CONUT as a predictor
Number of subjects: 336
Study 28928176 — intervention group
Group type: EXPERIMENTAL
Intervention: CONUT higher than 3.0
Number of subjects: 336
Study 25591053 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Tai Chi (10 different movements, 60 min, twice per week, for 6 weeks)
Number of subjects: 22
Study 25591053 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Tai Chi
Number of subjects: 22
Study 25591053 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 22
Study 22921688 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Pain Coping Skills Training (PCST)
Number of subjects: 20
Study 22921688 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Non-Directive Counseling (NDC)
Number of subjects: 20
Study 22397261 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient controlled analgesia (PCA) with morphine
Number of subjects: 71
Study 22397261 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral analgesia (FA) with 0.25% levobupivacain
Number of subjects: 71
Study 19111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate sprinkles
Number of subjects: 150
Study 19111318 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate drops
Number of subjects: 150
Study 16738295 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Macintosh laryngoscope blade
Number of subjects: 40
Study 16738295 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Miller laryngoscope blade
Number of subjects: 40
Study 16738295 — intervention group
Group type: COMPARATOR
Intervention: Original Macintosh laryngoscope blade
Number of subjects: 40
Study 16738295 — intervention group
Group type: COMPARATOR
Intervention: Original Miller laryngoscope blade
Number of subjects: 40
Study 15625464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy-assisted open reduction and internal fixation (AORIF)
Number of subjects: 72
Study 15625464 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation without arthroscopy (ORIF)
Number of subjects: 72
Study 11209968 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 and P replacement
Number of subjects: 30
Study 9373694 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVP display
Number of subjects: 0
Study 9373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Scroll display
Number of subjects: 0
Study 9373694 — intervention group
Group type: COMPARATOR
Intervention: Cataract simulators
Number of subjects: 0
Study 9373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity and contrast sensitivity
Number of subjects: 0
Study 9373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic text displays
Number of subjects: 0
Study 8405642 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate (AMX/CL) 2200 mg i.v. as a single dose
Number of subjects: 199
Study 8405642 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime plus metronidazole (CR/MN) 750/500 mg i.v. administered 3 times within 24 h
Number of subjects: 199
Study 8405642 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate (AMX/CL)
Number of subjects: 199
Study 8405642 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime plus metronidazole (CR/MN)
Number of subjects: 199
Study 3517256 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction group (received instruction about the unique physical and behavioral characteristics of premature infants)
Number of subjects: 30
Study 3517256 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention group (provided opportunity to discuss nonmedical concerns with the nurse researcher)
Number of subjects: 30
Study 3517256 — intervention group
Group type: COMPARATOR
Intervention: Control group (received routine care and support from the intensive care nursery staff)
Number of subjects: 30
Study 30829460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 1 year phoned physical activity advice individually adapted to physical assessment (twice a month during the first 6 months and then monthly)
Number of subjects: 301
Study 30829460 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - received current national recommendations in physical activity
Number of subjects: 301
Study 30829460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - breast cancer participants
Number of subjects: 301
Study 30829460 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - breast cancer participants
Number of subjects: 301
Study 30829460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - female participants
Number of subjects: 301
Study 30829460 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - female participants
Number of subjects: 301
Study 30829460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - normal nutritional status participants
Number of subjects: 301
Study 30829460 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - normal nutritional status participants
Number of subjects: 301
Study 29477692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN)
Number of subjects: 1095
Study 29477692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (monthly vs PRN)
Number of subjects: 1095
Study 29477692 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for month 24 MA presence
Number of subjects: 1095
Study 27445542 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 30
Study 27445542 — intervention group
Group type: COMPARATOR
Intervention: Routine pulmonary rehabilitation technique
Number of subjects: 30
Study 24456373 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA administered intravenously at weeks 0 and 2 (TWICE group)
Number of subjects: 20
Study 24456373 — intervention group
Group type: COMPARATOR
Intervention: CERA administered intravenously at week 0 (ONCE group)
Number of subjects: 20
Study 22156314 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (3 µg·kg(‐1)·min(‐1) for 24 h)
Number of subjects: 96
Study 22156314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no landiolol administration)
Number of subjects: 96
Study 22156314 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol group
Number of subjects: 96
Study 22156314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 20167278 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 25 mg/kg/day (arm A)
Number of subjects: 149